Chondrosarcoma: Clinical behavior, molecular mechanisms, and emerging therapeutic strategies.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: M.A.: Consultant: Aadi Bioscience, Boehringer Ingelheim, Deciphera, B.A.W.: Consultant: Aadi Bioscience, Boehringer Ingelheim, Deciphera, Inhibrx, SpringWorks, S.W.T.: Consultant/advisory board: Deciphera, Inhibrx, L.M.Z.: Consultant: Deciphera 4. J Am Acad Orthop Surg. 2021 Jul 1;29(13):553-562. doi: 10.5435/JAAOS-D-20-01188. Chondrosarcoma. Weinschenk RC(1), Wang WL, Lewis VO. Author information: (1)From the Department of Orthopaedic Oncology (Weinschenk, Lewis), and the Department of Pathology (Wang), The University of Texas MD Anderson Cancer Center, Houston, TX. Chondrosarcoma is the second most common primary bone tumor, with >90% of cases representing the primary conventional subtype. In addition to arising de novo, conventional chondrosarcoma can arise secondary to a benign underlying lesion, such as enchondroma or osteochondroma. Symptoms are often characterized by focal, dull, aching pain to the affected region. Grade is a well-recognized prognostic factor in these tumors. Grade I lesions/atypical cartilaginous tumors rarely metastasize, rarely recur, and have a 10-year survival rate of >80%. By contrast, grade III lesions are associated with a poor prognosis with the highest local recurrence rates, a lung metastasis rate of >50%, and a 10-year survival rate of